OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Abstract
Cost-effectiveness analysis (CEA) aims to evaluate the additional amount of health that an intervention provides to patients and how much more it costs compared to alternatives. While many health systems have used CEA for decades to inform coverage or reimbursement policies, in the US, it is now a contested political issue. One group of critics contend that CEA may be used to identify patient subgroups who are cost-ineffective to treat, resulting in treatment denials and discrimination. Recently, new perspectives on CEA argue that subgroups should be included to identify opportunities to advance health equity. Given these conflicting claims, this paper considers when subgroup analysis is justifiable and how results should be implemented.
This will be a hybrid seminar in the Richard Doll Building Lecture Theatre or on Zoom (medsci.zoom.us/j/92573286349).
